C-reactive protein-albumin-lymphocyte index predicts biochemical recurrence in prostate cancer
DOI:
https://doi.org/10.5489/cuaj.9414Keywords:
Biochemical recurrence, Prostate cancer, CALLY index, Prognostic marker, InflammationAbstract
Introduction: Systemic inflammation and nutritional status influence prostate cancer out-comes. The C-reactive protein-albumin-lymphocyte (CALLY) index integrates these param-eters, but its ability to predict biochemical recurrence (BCR) is not well-established.
Methods: In a single-center, retrospective cohort of 600 patients (2018–2022), the pre-treatment CALLY index was calculated as [albumin (g/dL) × lymphocytes (cells/μL)]/[CRP (mg/dL) × 10^4]. Patients were stratified by D’Amico risk. BCR was defined as prostate-specific antigen (PSA) ≥0.2 ng/mL after radical prostatectomy (confirmed) or ≥2.0 ng/mL above nadir after radiotherapy. Kaplan-Meier and Cox models evaluated associations; model performance was assessed using receiver operating curve (ROC), C-index, net reclassifica-tion improvement (NRI), and decision-curve analysis (DCA).
Results: Over a median followup of 28.4 months, 26.8% developed BCR. The optimal CAL-LY threshold was 1524.2, demonstrating modest discriminative ability (area under the curve [AUC] 0.684, 95% confidence interval [CI] 0.624–0.744; sensitivity 72.4%, specificity 64.8%). Low CALLY was associated with higher 36-month BCR rates (31.4% vs. 21.6%; log-rank p=0.042). In multivariable analysis, CALLY independently predicted BCR both as a continuous measure (per 100-unit increase: HR 0.882, 95% CI 0.778–0.998, p=0.048) and dichotomized at the median (HR 0.798, 95% CI 0.642–0.992, p=0.042), alongside baseline PSA and Gleason ≥4+4. Adding CALLY modestly improved discrimination of CAPRA (C-index 0.71→0.74) and Memorial Sloan Kettering Cancer Center (MSKCC) (0.73→0.76) models, with NRI 0.246 (p=0.006) and net clinical benefit on DCA across 10–40% thresh-olds. Effects were most pronounced in high-risk and surgically treated patients.
Conclusions: The pre-treatment CALLY index represents a readily available biomarker that independently predicts BCR and may complement established risk stratification tools in prostate cancer, although model performance was modest. External validation in prospective cohorts with longer followup is necessary before clinical implementation.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.
